These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24906535)

  • 21. Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.
    Ramaekers JG
    J Clin Psychiatry; 2003 Jan; 64(1):20-9. PubMed ID: 12590619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs of abuse, driving and traffic safety.
    Penning R; Veldstra JL; Daamen AP; Olivier B; Verster JC
    Curr Drug Abuse Rev; 2010 Mar; 3(1):23-32. PubMed ID: 20088818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.
    Pullen SJ; Wall CA; Angstman ER; Munitz GE; Kotagal S
    J Clin Sleep Med; 2011 Dec; 7(6):587-96. PubMed ID: 22171196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prevalence and nature of stopped on-the-road driving tests and the relationship with objective performance impairment.
    Verster JC; Roth T
    Accid Anal Prev; 2012 Mar; 45():498-506. PubMed ID: 22269535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD.
    Verster JC; Roth T
    J Clin Psychopharmacol; 2014 Oct; 34(5):633-6. PubMed ID: 24978156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychoactive medication and traffic safety.
    Verster JC; Mets MA
    Int J Environ Res Public Health; 2009 Mar; 6(3):1041-54. PubMed ID: 19440432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD).
    Sobanski E; Sabljic D; Alm B; Skopp G; Kettler N; Mattern R; Strohbeck-Kühner P
    J Neural Transm (Vienna); 2008; 115(2):347-56. PubMed ID: 18200437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drugs, driving, and traffic safety.
    WHO Offset Publ; 1983; (78):1-57. PubMed ID: 6673411
    [No Abstract]   [Full Text] [Related]  

  • 29. [Driving ability with alcohol and drug dependence and schizophrenia].
    Soyka M; Dittert S; Kagerer-Volk S; Soyka M
    Nervenarzt; 2014 Jul; 85(7):816-21. PubMed ID: 24906534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Automobile driving capacity of the elderly from the psychiatric viewpoint].
    Folkerts H
    Fortschr Med; 1993 May; 111(15):252-4. PubMed ID: 8330819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription drugs and driving performance.
    Lancet; 1984 Jul; 2(8394):112. PubMed ID: 6146005
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review : 70th Birthday Prof. Riederer.
    Brunnauer A; Laux G
    J Neural Transm (Vienna); 2013 Jan; 120(1):225-32. PubMed ID: 22684419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are actual driving tests necessary for evaluating drug safety?
    O'Hanlon JF
    Int Clin Psychopharmacol; 1988 May; 3 Suppl 1():81-5. PubMed ID: 3403953
    [No Abstract]   [Full Text] [Related]  

  • 34. Managing comorbid obesity and depression through clinical pharmacotherapies.
    McElroy SL; Guerdjikova AI; Mori N; Keck PE
    Expert Opin Pharmacother; 2016 Aug; 17(12):1599-610. PubMed ID: 27280311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Driving fitness in therapy with antidepressive drugs].
    Soyka M; Dittert S; Gartenmeier A; Schäfer M
    Versicherungsmedizin; 1998 Apr; 50(2):59-66. PubMed ID: 9587241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of chronic pain patients' psychotropic drug knowledge and warning labels on the decision whether to drive a car or not.
    Veldhuijzen DS; van Wijck AJ; Verster JC; Kalkman CJ; Kenemans JL; Olivier B; Volkerts ER
    Traffic Inj Prev; 2006 Dec; 7(4):360-4. PubMed ID: 17114093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dementia and driving].
    Brunnauer A; Buschert V; Laux G
    Nervenarzt; 2014 Jul; 85(7):811-5. PubMed ID: 24973013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Driving ability, mental illness and psychotropic medication in the elderly].
    Serra AL; von Gunten A; Mosimann U; Favrat B
    Rev Med Suisse; 2014 Apr; 10(428):981-5. PubMed ID: 24834622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence.
    Dassanayake T; Michie P; Carter G; Jones A
    Drug Saf; 2011 Feb; 34(2):125-56. PubMed ID: 21247221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.